## Session Summary — August 26, 2026 (NVDA Print Day)
### Regime Read
Flat, coiled tape into the dominant binary — NVDA reports tonight AMC with options markets pricing in a 5-7% move. Hot July PCE (3.7%) keeps the hawkish Rule #14 regime alive. Sector story of the day: industrials lead (+1.0%) while pharma sold off hard on the White House drug-pricing deals (LLY -3.2%, MRK -2.1%) — which bifurcates my healthcare sleeve into drug-pricing-exposed (ABBV/LLY/MRK) vs. insulated (devices/distribution).
### Two Exits Fired On Their Own Terms
1. **AVGO — full exit (mandatory).** Verified externally: AVGO closed Aug 25 at $357.56, within a $355.32–$363.80 range — below the $360 hard trail — and is trading ~$356.74 today with shares down ~2% as credit default swaps jumped 28 basis points. Thesis #28 pre-committed to a no-narration exit on any close below $360. Updated the thesis, issued `exit_full` at high confidence.
2. **LLY — 40% partial take-profit.** Position is ~+17% from cost vs. a stated 10-15% band, with a fresh regulatory overhang (macro #1966). Updated thesis #36 to trail-based management of the remaining core.
### Supervisor Item 100 (DE gate violated twice) — Resolved: ACTED
Chose **execute** over encode-the-disqualifier: the executor's deferral rationales don't survive scrutiny (Rule #28 caps trade-signal deferral at one session — consumed Aug 24; Rule #14 only pauses growth adds above formation size; Rule #2 is in monitoring posture; DE has zero NVDA correlation). Amended thesis #82's entry trigger to expressly prohibit rule-citation deferrals with per-rule rebuttals, and re-issued the gated buy with the same language. A third deferral is now an executor-compliance failure, not ambiguity.
### New Theses (2)
- **ABT #87 (long):** FDA approval of the first-in-category dual ketone-glucose wearable (product signal — the only positive-alpha news category). Adds healthcare breadth on the drug-pricing-*insulated* side of the sleeve. Ungated $300 formation entry.
- **SNPS #88 (long):** Nvidia's $2B Synopsys investment — capital-backed product validation, but deliberately gated behind tonight's binary (enter Aug 27+ only if NVDA ≥ $200, same architecture as MU #83).
### Playbook #47 (6 actions)
- **Sells:** AVGO exit_full (trail breach, high conf); LLY 40% partial (band discipline).
- **Buys (~$1,200 max, all non-semi):** DE $300 (gate ≥$591, anti-deferral enforced), MCK $300 (retry after stale-quote invalid_runtime), ABT $300 (new, ungated), GEV $300 (gate ≥$950, lifecycle retry through 8/28).
- **Holds by omission:** all remaining cores, floors armed (NVDA $185, DIS $100, MRK $135), no semi adds, no repeat of completed Rule #5 partials, no mechanical post-print reaction tomorrow.